Chronic Myeloid Leukemia


Bosutinib Evaluated for Initial Treatment of Patients with CML (June 17, 2011)

Researchers involved in an international study have reported that a new tyrosine kinase inhibitor, bosutinib, appears to be superior to Gleevec® (imatinib) for the initial therapy of patients with chronic... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

CML Patients Treated with Gleevec Have Normal Life Expectancy (March 31, 2011)

People with chronic myeloid leukemia (CML) that is in complete remission after two years of treatment with Gleevec® (imatinib) have survival rates that are similar to those of the general population.... Continue Reading

Tasigna Improves Outcomes in Newly Diagnosed CML (December 10, 2010)

According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed... Continue Reading

Sprycel® Approved for Initial Treatment of Chronic Myeloid Leukemia (November 5, 2010)

The U.S. Food and Drug Administration has expanded the approval of Sprycel® (dasatinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic... Continue Reading

Tasigna Approved for Initial Treatment of Chronic Myeloid Leukemia (June 22, 2010)

The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic... Continue Reading

Sprycel May Be More Effective than Gleevec for Initial Treatment of CML (June 5, 2010)

In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading

Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant (April 29, 2010)

For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar... Continue Reading

Tasigna May Be More Effective than Gleevec for Initial Treatment of CML (January 28, 2010)

In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009... Continue Reading

« Previous PageNext Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS